Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
about
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug developmentCreatine for treating muscle disordersCreatine for treating muscle disordersCreatine for treating muscle disordersPhosphorylation of profilin by ROCK1 regulates polyglutamine aggregationExendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's diseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylationRole of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesisMitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington diseaseHighly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's diseaseInternational Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicineCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseTauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.Targeting cellular energy production in neurological disorders.Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant miceA review of creatine supplementation in age-related diseases: more than a supplement for athletes.Clinical and research advances in Huntington's disease.In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 miceMutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's diseaseCardiac dysfunction in the R6/2 mouse model of Huntington's diseasePharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's diseaseExperimental therapeutics in transgenic mouse models of Huntington's disease.Kennedy's disease: pathogenesis and clinical approaches.Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.Development of novel therapies for Huntington's disease: hope and challenge.
P2860
Q22241837-D0D39B7C-D6D7-4DDA-9C62-B445AEDD4047Q24202243-2891A558-B88A-4A48-8278-E8DBC1354C37Q24236598-CF4B92BD-127F-40CC-BEC3-51E9E9FB1E15Q24246414-9EFF8291-5B15-44C5-9B3D-884A10D9F670Q24324878-570D30C2-B193-4553-9F78-9C9183116014Q24647189-674978C2-EDB2-47C4-B6F8-5E997A373344Q27005950-62AAA58D-2896-48A7-BA97-121B70B6A062Q27314860-CA1F40D6-DD99-417C-877B-AB78BB8578A7Q28305798-D1691B2E-86DC-4B33-AEED-2200F17CB918Q28386202-D2C5DE5F-2F56-4B0F-A485-F7337300A454Q28386769-54473CDF-60E8-475B-A408-8E54099887BBQ30446460-A91AF57B-0420-44AC-8136-5696F107659FQ30480065-643CF2D3-36B5-4B5B-9F24-EC93C2472141Q30954808-1C7137C9-E384-4CC3-B96E-9C2642651A9EQ31002507-115A4648-D515-4E89-80F3-FCA96C5596F6Q33271816-0BFCBC05-D69F-4C43-802D-14B897FC1501Q33551416-42B5BC11-CBCA-4860-ADFB-83B6A68390A5Q33649916-2E6BE48A-1033-4941-9421-A282E31F679AQ33687436-997D6F7D-B976-4F6F-907E-4A9B7DF100B9Q33713689-BF5E0A90-2213-42B5-A0F1-5C654F58D9FDQ33769984-321DA714-2FF1-4B17-9F95-13FF6089BAC1Q33791877-10EBAB28-086A-4231-95D5-1EBA57EDF986Q33837238-207E0A00-5FE7-4D39-A502-6A25E8F4F49CQ33917550-75EE89BE-C06C-460B-A04E-75AB158AC5E2Q33936969-DA936395-5AE0-46D6-8D39-3C20CC0F9758Q34043950-3A211EA3-091F-4EF3-B5A9-BC9DCC5C85FCQ34075502-BF777CCC-577E-41A6-8A52-2A48690D1897Q34266266-DA7BAD8D-5CB2-4EBE-AFE4-1EE32116A2EDQ34711201-5821DFF6-A910-4BB4-9230-0B20458CB41DQ34809057-8835EBD4-74D1-4395-81A9-89BB4A4CACBAQ35005568-1B17EB86-DB5E-44C0-AD0F-5B3E8E9A65FDQ35105749-9CE81ABA-8F70-4793-84D6-77489C8812E7Q35565488-E61F8A02-59C6-45C8-8155-55C470A9B8B2Q35645271-174EA622-6C1A-44FB-9019-A711D48F10C7Q35745626-997609EE-0495-4CD8-B011-AB9D9897C7D1Q35750228-8ACF7AA2-97B6-4982-AA34-0FB2D74879D3Q35752429-D9071525-7EB0-467F-AB1B-C97884FF2678Q35777504-4B98D35C-0D20-4730-9F43-311CBC2D5907Q35880053-9C342BF0-8C13-474B-818C-6521FBF39CFBQ36016932-E9881C43-D6A4-4278-9B3D-0FB114E5C204
P2860
Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Creatine increase survival and ...... model of Huntington's disease.
@en
Creatine increase survival and ...... model of Huntington's disease.
@nl
type
label
Creatine increase survival and ...... model of Huntington's disease.
@en
Creatine increase survival and ...... model of Huntington's disease.
@nl
prefLabel
Creatine increase survival and ...... model of Huntington's disease.
@en
Creatine increase survival and ...... model of Huntington's disease.
@nl
P2093
P356
P1476
Creatine increase survival and ...... model of Huntington's disease.
@en
P2093
A Friedlich
B G Jenkins
D R Borchelt
G Schilling
K L Ferrante
R J Ferrante
S E Browne
P304
P356
10.1006/NBDI.2001.0406
P577
2001-06-01T00:00:00Z